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Abstract 
Background: Surgical interventions such as shunts and devascularisation procedures are effective 
therapies to prevent variceal rebleeding in people with hepatosplenic schistosomiasis. As this disease is 
prevalent in low income countries, the impact of eco-social factors result in poor compliance with non-
surgical therapies that require repeated sessions and long-term follow-up. 
Objectives: To determine whether surgical portosystemic shunts have better outcomes compared with 
oesophagogastric devascularisation procedures in the prevention of variceal rebleeding due to 
schistosomal portal hypertension (SPH). 
Methodology: This meta-analysis was conducted using standards expected by The Cochrane 
Collaboration. All randomised clinical trials comparing surgical portosystemic shunts with 
oesophagogastric devascularisation with or without splenectomy in the prevention of variceal rebleeding 
due to hepatosplenic schistosomiasis were selected. The risks of bias were assessed according to domains 
and risk of random errors with Trial Sequential Analysis. The quality of evidence was assessed using the 
Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) Working Group 
approach. 
Results: Two trials met the inclusion criteria of this review and were selected. An analysis of 115 
participants, 57 who received distal splenorenal shunt (DSRS) and 58 who received devascularisation 
procedure is presented. The trials were assessed at high risk of bias. There is no difference in overall 
mortality between DSRS versus devascularisation, risk ratio (RR) is 1.40, (95% confidence interval (CI) 
0.32 to 6.15), downgraded to very low quality due to overall risk of bias, imprecision and publication 
bias. Variceal rebleeding following devascularisation is statistically significant higher than after DSRS 
(RR is 0.23, 95% CI 0.05 to 1.01), very low quality evidence due to bias, imprecision, and publication 
bias. The number of participants needed to treat with DSRS to achieve benefit (NNTB) is 8. Serious 
adverse events reported as procedure specific include: portal vein thrombosis, haemolysis, ascites and 
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shunt dysfunction. There was no report on quality of life. DSRS is associated with a statistically 
significant higher post procedure encephalopathy (RR 8.10, 95% CI 1.04 to 62.83), downgraded to very 
low quality due to overall risk of bias, imprecision, and publication bias. Trial sequential analysis shows 
no strong evidence to accept or reject the difference in variceal rebleeding and encephalopathy rate for 
both interventions because of bias and inadequate sample size. Outcomes of proximal splenorenal shunt 
(PSRS) compared to devascularisation were reported by a single trial, therefore no meta-analysis was 
computed for this comparison, nor subgroup of PSRS compared to DSRS. 
Conclusion: Available evidence seems to suggest that DSRS is better than devascularisation for the 
prevention of variceal rebleeding due to hepatosplenic schistosomiasis, but this is at the cost of significant 
encephalopathy. The review authors are cautious to make this conclusion because overall evidence is very 
low quality and only few trials with small sample size are available. Further randomised clinical trials 
with adequate sample size and good methodological quality are needed. 
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Section 1: Literature Review 
1.1 Background  
Oesophagogastric varices occur in patients that suffer from portal hypertension either as 
sequelae of liver cirrhosis or with presinusoidal causes such as schistosomiasis. In portal 
hypertension there is a pathological increase in the portocaval pressure gradient (Sanyal et al, 
2008) resulting in the development of varices, encephalopathy, hypersplenism and ascites 
(Goff et al, 1993). Portal Hypertension is defined as a portal venous pressure gradient greater 
than 8mmHg and clinically relevant variceal bleeding occur when the pressure gradient 
exceeds 12mmHg (Sanyal et al. 2008).  Variceal bleeding is a significant cause of mortality 
in patients with portal hypertension (approximately 50% from the first bleed in liver 
cirrhosis) (Graham & Smith, 1981; de Dombal, et al. 1986). In survivors of the first episode, 
recurrent bleeding is not uncommon and the risk of rebleeding is greatest within the first 
thirty days that follow the initial bleed (Smith & Graham, 1982).  
1.2 Treatment of Variceal Bleeding 
The algorithm for the control of acute variceal bleeding is the same for both cirrhotic and 
non-cirrhotic portal hypertension, consisting of a combination of pharmacological (vasoactive 
agent) and endoscopic therapy. Using this management, bleeding will stop in 90% of people 
(D'Amico et al, 2003; Gonzalez et al, 2008; de Franchis, 2010). The remaining 10% are 
classified as people with refractory bleeding, and further management options include 
radiologically placed transjugular intrahepatic portosystemic shunt (TIPS) or surgical 
interventions (shunt, devascularisation procedures, or liver transplantation) (de Franchis, 
2010). The risk of long-term rebleeding without further intervention following the control of 
acute variceal bleeding is approximately 80% (Kiire, 1989; D'Amico et al, 1995; Vleggaar et 
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al, 1998), hence secondary prevention is required in any person who has suffered a variceal 
bleed (de Franchis, 2010). 
1.3 Prevention of variceal rebleeding  
Medical treatment (combined endoscopic band ligation and non-selective beta-blockers) is an 
effective first-line modality to prevent variceal rebleeding (de Franchis 2010; Sarin et al, 
2010). This requires repeated treatment sessions.  However, approximately 20% to 30% of 
people who receive medical therapy will still have recurrent variceal bleeding while 
undergoing treatment (Kiire et al, 1989; Bhargava et al 1990; Vleggaar et al, 1998; Sarin et 
al, 2010).  
TIPS has an efficacy of more than 90% rebleed-free rate and is recommended as rescue 
therapy following the failure of medical treatment in persons with cirrhosis (Rossle et al, 
2006; Boyer & Haskal, 2010; de Franchis 2010). Although it is a less invasive procedure than 
a surgical procedure, it may have more complications and requires more re-interventions than 
surgical procedures. In the era of radiological shunt (TIPS), the use of surgical shunts and 
devascularisation procedures have decreased as TIPS offers a minimally invasive alternative 
and serve as a bridge to liver transplantation (John et al. 1996; Boyer & Haskal, 2010). 
Nonetheless, only 3% to14% of eligible cirrhotic patients eventually receive liver transplant 
(Rosemurgy et al. 2012; Toomey et al. 2013). However, people with schistosomal portal 
hypertension do not meet liver transplantation criteria as their liver function is preserved 
(Rosemurgy 2012).The long term patency of TIPS as well as long term survival rates are less 
than surgical shunts (Rosemurgy et al. 1996; Orloff et al, 2014). The 5-year patency and 
survival rate for a surgical shunt is 97% and 68% respectively (Gur et al.  2014). The median 
survival after TIPS is 26 months compared to 52 months after H-graft portocaval shunt  
(Rosemurgy et al. 2012). Early shunt occlusion occurred within 30 days in 17% of patient 
after TIPS compared to 9% after surgical shunt (Rosemurgy et al. 1996).  This data is only 
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valid in cirrhotic patients. However, there is no literature to my knowledge supporting the use 
of TIPS in schistosomal portal hypertension (SPH) (Eesa & Clark, 2011). 
In SPH hepatic venous pressure and hepatic function are largely preserved if there are no 
other concomitant liver diseases such as viral hepatitis infection (Denie et al. 1996; Bica et 
al. 2000). There is good data to support the use of surgical shunts for portal decompression in 
SPH as this subgroup of patients are young with preserved liver function (Henderson, 1988; 
Spina et al, 1992; Ferraz et al, 2001; Gur et al, 2014). 
The aim of surgery is to reduce the high pressure in the portal circulation. This is achieved by 
diverting portal venous blood into the systemic circulation. Generally, two types of 
procedures are described, shunts and devascularisation (Da Silva & Carrilho, 1992). Surgical 
shunts are traditionally divided into selective and non-selective types. When compared to 
selective shunts, the non-selective shunts divert all portal blood away from the liver into the 
systemic circulation resulting in reduction in effective hepatic blood flow. The risk of 
encephalopathy after non-selective shunt in SPH approach 39%, hence selective shunts are 
advocated (Raia et al, 1994; Andersson & Chung, 2007). Perioperative mortality following 
shunt procedures is 6%, with 5-year survival rate of 68-75% (Paquet et al.1989; Rikker et al, 
1992; Orloff et al. 2009; Gur et al, 2014). 
On the other hand, devascularisation procedures have higher rebleeding rate of 7-40% 
(Henderson, 1988; Johnson et al. 2006), compared to surgical shunt with rates of 5-11% 
depending on the type of shunt (Rikkers et al, 1998). Also the risk of encephalopathy with 
devascularisation is rare and overall operative mortality higher at 13% (Suigura & Futagawa, 
1984; Rikkers et al, 1998; Qazi et al, 2006). Hence, devascularisation procedures have higher 
mortality and a disappointing long term outcome because of high rate of rebleeding compared 
to selective surgical shunt. 
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1.4 Description of the condition 
Schistosomiasis is a parasitic disease that is endemic in poor communities with inadequate 
sanitation and lack of access to portable water (Steinmann et al, 2006). The World Health 
Organisation estimates that the total number of people infected worldwide is over 200 
million. More than 90% of these live in Africa (WHO, 2014). The hepatosplenic form of the 
disease is caused by two species of the blood fluke Schistosoma, namely S. mansoni found 
predominantly in Africa, Arabia and South America, and S. japonicum found in South-East 
Asia, especially mainland China.  
1.4.1 Life cycle of Schistosoma spp 
Human infestation starts with bite by the cercariae when there has been contact between the 
skin and infested water. These larvae are transformed into schistosomulae in bloodstream and 
subsequently mature into adult worms in the mesenteric veins. Mating between the male and 
female adult worms occurs within the mesenteric veins and results in release of eggs by the 
female worm. A granulomatous inflammatory reaction to the trapped eggs in portal vein 
radicles results in periportal fibrosis, also called Symmer’s clay pipe stem fibrosis (Symmers, 
1904). It is this fibrous occlusion of portal vein radicles that results in the development of 
presinusoidal portal hypertension (Ross et al. 2002). 
1.5 Description of interventions 
The two main categories of surgical procedures to prevent variceal rebleeding are 
portosystemic shunts and devascularisation procedures.  
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1.5.1 Surgical portosystemic shunt 
 These are surgically created conduits that divert some or all of portal venous blood away 
from the liver into the systemic circulation. These conduits may be autogenous vein graft or 
polytetrafluoroethylene prosthesis (PTFE). Commonly created surgical portosystemic shunts 
include the non-selective H-shunt and the selective DSRS (Warren, 1967). The H-shunt is 
created between the portal vein and the inferior vena cava using an 8 mm to 16 mm ringed 
PTFE prosthesis. The PTFE graft is non expansible and by diminishing its diameter from 
16mm to 8mm a partial portal decompression is achieved (Sarfeh et al, 1986; Sarfeh et al, 
1994). 
The DSRS is created by anastomosing the distal splenic vein to the left renal vein and 
disconnecting the splenopancreatic and gastric venous connections to the portal system while 
preserving portal venous blood flow and hepatic function. 
1.5.2 Oesophagogastric devascularisation procedures 
This involves trans-hiatal devascularisation of the lower oesophagus and proximal half of the 
stomach, with ligation of branches of left gastric, short gastric, left gastroepiploic, and 
perforating oesophageal arteries and veins. This is combined with splenectomy (Hassab, 
1967), or with oesophageal transection plus splenectomy in a two-stage operation (Sugiura & 
Futagawa, 1973). The original Sugiura procedure was subsequently modified into a one-stage 
abdominal procedure (Peracchia et al, 1980; Inokuchi, 1985), or without oesophageal 
transection (Jin & Rikkers, 1996; Johnson et al, 2006), or without truncal vagotomy 
(Ginsberg 1982), and without splenectomy (Orozco et al, 1998). One randomised clinical 
trial comparing devascularisation with splenectomy or without splenectomy showed no 
statistically significant difference in outcome between the two methods; however, there was a 
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significant increase in transfusion requirement in the splenectomy group. This trial 
demonstrates that splenectomy may not be mandatory in devascularisation procedure (Orozco 
et al, 1998). 
1.6 How the interventions might work 
Surgical portosystemic shunts and devascularisation procedures decrease portal venous 
pressure, and hence decrease portal hypertension, which consequently prevents variceal 
bleeding. Oesophagogastric devascularisation with or without splenectomy reduces portal 
hypertension by decreasing portal blood flow, but with a compensatory increase in hepatic 
artery flow. This maintains effective hepatic blood flow and preserves liver function. The 
procedure normalises the hyperdynamic circulatory state present in schistosomal portal 
hypertension (de Cleva et al, 2007; Zhang et al, 2009; Evangelista-Neto et al, 2012). 
1.7 Why is this review important? 
To date no meta-analysis or systematic review has compared surgical portosystemic shunts to 
devascularisation procedures in control of recurrent variceal bleeding due to schistosomal 
portal hypertension.  
Yin et al in a meta-analysis of selective shunt, non-selective shunt, devascularisation, and a 
combined procedure (shunts plus devascularisation) in prevention of both cirrhotic and non-
cirrhotic variceal bleeding, concluded that the combined procedure was the best choice for 
secondary prophylaxis of variceal rebleeding (Yin et al, 2013). They did not separate the 
results of people with and without cirrhosis in their review. Therefore this meta-analysis will 
compare the outcome of two surgical interventions (shunts and devascularisation) for the 
prevention of variceal rebleeding due to SPH. 
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Section 2: Draft article to Cochrane Database of Systematic review 
This review has been approved by the Cochrane hepatobiliary group (CHBG) and the 
protocol published in Cochrane Database of Systematic review. The protocol citation is as 
follows: 
Ede CJ, Brand M. Surgical portosystemic shunts versus devascularisation procedures for 
variceal bleeding due to hepatosplenic schistosomiasis [Protocol]. Cochrane Database of 
Systematic Reviews 2015, Issue 5. Art. No.: CD011717. DOI: 10.1002/14651858.CD011717. 
The final review has been completed and submitted to the editorial team of CHBG on 
17/8/2016 
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Abstract 
Background 
Surgical interventions such as shunts and devascularisation procedures are effective therapies 
to prevent variceal rebleeding in people with hepatosplenic schistosomiasis. As this disease is 
prevalent in low income countries, the impact of eco-social factors result in poor compliance 
with non-surgical therapies that require repeated sessions and long-term follow-up. 
Objectives 
To determine whether surgical portosystemic shunts have better outcomes compared with 
oesophagogastric devascularisation procedures in the prevention of variceal rebleeding due to 
schistosomal portal hypertension. 
Search Methods 
We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane 
Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation 
Index Expanded and reference lists and proceedings of relevant associations for relevant trials 
up until May 2016. 
Selection criteria 
All randomised clinical trials comparing surgical portosystemic shunts with oesophagogastric 
devascularisation with or without splenectomy in the prevention of variceal rebleeding due to 
hepatosplenic schistosomiasis were selected. Trials that included participants with 
concomitant cirrhosis or who had undergone TIPS were excluded. 
Data collection and analysis 
We conducted data extraction and assessment of methodological quality using standards 
expected by The Cochrane Collaboration. We assessed risk of bias according to domains and 
risk of random errors with Trial Sequential Analysis. The quality of evidence was assessed by 
the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) 
Working Group approach. 
Main results 
Two trials that met the inclusion criteria of this review were selected. An analysis of 115 
participants, 57 who received distal splenorenal shunt and 58 who received devascularisation 
procedure is presented. The trials were assessed at high risk of bias. There is no difference in 
overall mortality between distal splenorenal shunt versus devascularisation, risk ratio (RR) is 
1.40, (95% confidence interval (CI) 0.32 to 6.15), downgraded to very low quality due to 
16 
 
over-all risk of bias, imprecision and publication bias. Variceal rebleeding following 
devascularisation is statistically significant higher than after DSRS (RR is 0.23, 95% CI 0.05 
to 1.01), very low quality evidence due to bias, imprecision, and publication bias. The NNTB 
is 8. Serious adverse events reported as procedure specific include: portal vein thrombosis, 
haemolysis, ascites and shunt dysfunction. There was no report on quality of life. DSRS is 
associated with a statistically significant higher post procedure encephalopathy (RR 8.10, 
95% CI 1.04 to 62.83), downgraded to very low quality due to overall risk of bias, 
imprecision, and publication bias. Trial sequential analysis shows no strong evidence to 
accept or reject the difference in variceal rebleeding and encephalopathy rate for both 
interventions because of bias and inadequate sample size. Outcomes of PSRS compared to 
devascularisation were reported by a single trial, therefore no meta-analysis was computed 
for this comparison, nor subgroup of PSRS compared to DSRS. 
 
Authors’ conclusions 
Available evidence seems to suggest that DSRS is better than devascularisation for the 
prevention of variceal rebleeding due to hepatosplenic schistosomiasis, but this is at the cost 
of significant encephalopathy. The review authors are cautious to make this conclusion 
because overall evidence is very low quality and only few trials with small sample size are 
available. We suggest further randomised clinical trials with adequate sample size and 
methodological quality. 
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Background 
Portal hypertension refers to the pathological increase of the hepatic venous pressure 
gradient, in other words the pressure gradient between the portal vein and inferior vena cava 
is increased (Sanyal 2008). Manometrically, portal hypertension is defined as hepatic venous 
pressure gradient greater than 8 mmHg, and clinically obvious variceal bleeding occurs when 
the pressure gradient exceed 12 mmHg (Sanyal 2008). This is a hallmark of liver cirrhosis; 
however, bleeding may also be caused by non-cirrhotic conditions such as hepatosplenic 
schistosomiasis. The sequelae of portal hypertension include the development of varices, 
encephalopathy, hypersplenism, and ascites (Goff 1993). 
Unlike liver cirrhosis in which there is destruction of liver architecture with concomitant loss 
of hepatocyte function, the hepatosplenic form of chronic schistosomiasis causes 
presinusoidal portal hypertension (Ross 2002) where hepatic architecture and function are 
preserved in the absence of concomitant liver disease such as viral hepatitis infection (De 
Cock 1986; Denié 1996; Bica 2000). Despite schistosomiasis control issues, current evidence 
suggest high prevalence of the disease in Africa and the burden of undiagnosed hepatosplenic 
form remains high (Payne 2013). An East African study demonstrated that isolated 
hepatosplenic schistosomiasis accounted for a third of oesophageal varices in their population 
(De Cock 1982). 
Oesophagogastric variceal bleeding is the most lethal complication of portal hypertension as 
the mortality from the first bleeding episode is approximately 15% to 20% in cirrhotic portal 
hypertension (Chalasani 2003; Carbonell 2004; Villanueva 2006), and 10% in non-cirrhotic 
portal hypertension (Chofle 2014). Recurrent bleeding is not uncommon in survivors of the 
first episode and is also associated with a similar mortality. The greatest risk of rebleeding is 
during the first thirty days following the initial variceal bleeding (Smith 1982). 
The algorithm for the control of acute variceal bleeding is the same for both cirrhotic and 
non-cirrhotic portal hypertension, consisting of a combination of pharmacological (vasoactive 
agent) and endoscopic therapy. Using this management, bleeding will stop in 90% of people 
(D'Amico 2003; Gonzalez 2008; de Franchis 2010). The remaining 10% are classified as 
people with refractory bleeding, and further management options include radiologically 
placed TIPS or surgical interventions (shunt, devascularisation procedures, or liver 
transplantation) (de Franchis 2010). The risk of long-term rebleeding without further 
intervention following the control of acute variceal bleeding is approximately 80% (Kiire 
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1989; D'Amico 1995; Vleggaar 1998), hence secondary prevention is considered required in 
any person who has suffered a variceal bleed (de Franchis 2010). 
Medical treatment (combined endoscopic band ligation and non-selective beta-blockers) is an 
effective first-line modality to prevent variceal rebleeding (de Franchis 2010; Sarin 2010). 
However, approximately 20% to 30% of people will still have recurrent variceal bleeding 
while being treated with medical therapy (Kiire 1989; Bhargava 1990; Vleggaar 1998; Sarin 
2010). Therefore, patients are usually offered repeated sessions of endoscopy with 
sclerotherapy or banding to obliterate the varices. This may have cost and travel implications 
for the person and health system, specifically in resource-poor areas where schistosomiasis is 
endemic. Although surgical options for preventing variceal rebleeding are only considered as 
an alternative strategy when medical therapy fails, they may well be a one-stop procedure 
which entails fewer hospital visits, and less intensive follow-up (Henderson 2005; Pal 2012). 
TIPS has an efficacy of more than 90% rebleed free rate and is recommended as rescue 
therapy following the failure of medical treatment (Rossle 2006; Boyer 2010; de Franchis 
2010). Although it is a less invasive procedure than a surgical procedure, it may have more 
complications and requires more re-interventions than surgical procedures. The occlusion and 
stenosis rate for TIPS is 17% compared with 9% for surgical shunts (Rosemurgy 2012); 
rebleeding occurs in 20% to 30% of people compared with less than 10% for surgical shunts; 
a median survival of 26 months compared with 52 months for surgical shunts (Rikkers 1998; 
Costa 2010; Rosemurgy 2012), and post shunt encephalopathy rate ranges between 18% and 
45% (Rossle 1994; Deng 2006). In addition, TIPS requires more intensive long-term 
surveillance than surgical shunts due to their higher occlusion rates and resulting more 
frequent need for re-intervention, up to 21% for TIPS versus 6% for surgical shunts (Toomey 
2013). There is no literature to our knowledge supporting the use of TIPS in SPH (Conn 
1993; Eesa 2011). 
Liver transplantation is an effective treatment for the definitive control of variceal rebleeding 
in people with end-stage liver disease (de Franchis 2010; Rosemurgy 2012), yet only 3% to 
14% of people with cirrhosis complicated by variceal bleeding eventually receive 
transplantation post TIPS (Stanley 1996; Tripathi 2004; Rossle 2006; Rosemurgy 2012; 
Toomey 2013). However, people with SPH do not meet liver transplantation criteria as their 
liver function is preserved (Rosemurgy 2012). 
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Surgical shunts are considered for people with good performance status and Child-Pugh class 
A or early B (Child 1964; Pugh 1973; Garcia-Tsao 2010; Orloff 2012; Gur 2014). On the 
basis of their haemodynamic effect on portal circulation, surgical shunts are divided into 
selective and non-selective types. Non-selective shunts totally bypass portal blood flow into 
the systemic circulation, as opposed to selective shunts which maintain nutrient hepatic blood 
flow. A recent meta-analysis concluded that the rebleeding rate, encephalopathy, and late 
mortality are comparable for selective and non-selective shunts (Yin 2013). However, it has 
been argued that total portal decompression may precipitate encephalopathy in up to 39% of 
people with preserved liver function, such as people with SPH (Raia 1994). Therefore, 
selective shunts are considered to be superior to non-selective shunts in this subgroup 
(Henderson 1988; Da Silva 1992; Conn 1994; Raia 1994; Andersson 2007). Overall 
perioperative mortality following shunt procedures is 6% to 15%, with five-year survival 
rates approaching 80% in cirrhotics in whom mortality occurs as a result of progressive 
hepatic decompression (Rosemurgy 2012; Gur 2014). The survival data for non-cirrhotics 
such as hepatosplenic schistosomiasis exceed cirrhotics (Raia 1994, Gawish 2000) 
Devascularisation procedures are effective rescue options in people where vascular anatomy 
is unsuitable for shunt surgery, such as extensive splenoportal thrombosis. However, the 
further role of devascularisation procedures remains controversial due to the high morbidity 
and mortality when compared with shunts in certain patient series (Selzner 2001). Overall 30-
day operative mortality following devascularisation procedures ranges from 13% to 24% 
(Rikkers 1998; Qazi 2006; Voros 2012), and variceal rebleed rates up to 40% have been 
reported (Henderson 1988; Orozco 1992; Johnson 2006). However, the risk of 
encephalopathy is rare (Conn 1994; Raia 1994), and there is no need for post-procedure 
surveillance of shunts. Overall five-year survival is approximately 75% and is comparable to 
shunt procedures (Ezzat 1990; Orozco 1992). A significant procedure-specific morbidity is 
oesophageal anastomotic leak, which may be as high as 10% (Voros 2012). 
Yin 2013 in a meta-analysis of selective shunt, non-selective shunt, devascularisation, and 
shunts plus devascularisation in control of both cirrhotic and non-cirrhotic variceal bleeding, 
concluded that the combined procedure was the best choice for secondary prophylaxis of 
variceal rebleeding (Yin 2013). They did not separate the results of people with and without 
cirrhosis in their review. 
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Description of condition 
Schistosomiasis is a parasitic disease that is endemic in poor communities with inadequate 
sanitation and lack of access to potable water (Steinmann 2006). The World Health 
Organization (WHO) estimates that the total number of people infected worldwide is over 
200 million with more than 90% of total infected people living in Africa (WHO 2014). The 
life cycle of this parasite involves two hosts namely human (the definitive host) and snail (the 
intermediate host). Human host become infected by contact with infested water where 
cercariae released by infected snail of the genus Bomphalaria penetrate the skin or mucosa, 
or both. Further maturation takes place in the lungs and liver to produce adult worms that 
migrate to the mesenteric vein where they mate and deposit their eggs. There are several 
species of the blood fluke, Schistomatidae family, but the two species namely Schistosoma 
mansoni found predominantly in Africa, Arabia, and South America, and Schistosoma 
japonicum found in South-East Asia, especially mainland China, are responsible for the 
hepatosplenic form of the disease (Colley 2014a). Available evidence suggests an immune-
mediated granulomatous inflammatory reaction to the trapped eggs in portal vein radicles 
results in periportal fibrosis also called Symmer's pipe-stem fibrosis (Symmers 1904; Burke 
2009; Colley 2014). This fibrosis subsequently results in the development of pre-sinusoidal 
portal hypertension (Ross 2002). 
The prevalence of portal hypertension in schistosomiasis endemic areas approaches 18% in 
the absence of a schistosomiasis control programme (Mudawi 2007), of these 30% to 60% 
will develop varices (De Cock 1982; Saad 1991). 
Description of intervention 
The two categories of surgical procedure that were compared are portosystemic shunts versus 
devascularisation procedures. 
(i). Portosystemic shunts are surgically created conduits that divert some or all of portal 
venous blood away from the liver into the systemic circulation. These conduits may be 
autogenous vein graft or polytetrafluoroethylene prosthesis. Commonly created surgical 
portosystemic shunts include the non-selective H-shunt and the selective DSRS (Warren 
1967). 
The H-shunt is created between the portal vein and the inferior vena cava using an 8 mm to 
16 mm ringed polytetrafluoroethylene prosthesis. The PTFE graft is non expansible and by 
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diminishing its diameter from 16mm to 8mm a partial portal decompression is achieved 
(Sarfeh 1986; Sarfeh 1994). 
The DSRS is created by anastomosing the distal splenic vein to the left renal vein and 
disconnecting the splenopancreatic and gastric venous connections to the portal system while 
preserving portal venous blood flow and hepatic function. 
(ii). Oesophagogastric devascularisation includes transhiatal devascularisation of the lower 
oesophagus and proximal half of the stomach, with ligation of branches of left gastric, short 
gastric, left gastroepiploic, and perforating oesophageal arteries and veins. This is combined 
with splenectomy (Hassab 1967), or with oesophageal transection plus splenectomy in a two-
stage operation (Sugiura 1973). The original Suguira procedure was subsequently modified 
into a one-stage abdominal procedure (Peracchia 1980; Inokuchi 1985), or without 
oesophageal transection (Jin 1996; Johnson 2006), or without truncal vagotomy (Ginsberg 
1982), and without splenectomy (Orozco 1998). One randomised clinical trial comparing 
devascularisation with splenectomy or without splenectomy showed no statistically 
significant difference in outcome between the two methods; however, there was a significant 
increase in transfusion requirement in the splenectomy group. This trial demonstrates that 
splenectomy may not be mandatory in devascularisation procedure (Orozco 1998). 
How the intervention might work 
Surgical portosystemic shunts and devascularisation procedures decrease portal venous 
pressure, and hence decrease portal hypertension, which consequently prevents variceal 
bleeding. 
Oesophagogastric devascularisation with splenectomy reduces portal hypertension by 
decreasing portal blood flow, but with a compensatory increase in hepatic artery flow. This 
maintains effective hepatic blood flow and preserves liver function. The procedure 
normalises the hyperdynamic circulatory state present in schistosomal portal hypertension (de 
Cleva 2007; Zhang 2009; Evangelista-Neto 2012). 
Why it is important to do this review 
To date, no meta-analysis or systematic review has compared surgical portosystemic shunts 
versus devascularisation procedures to prevent variceal rebleeding due to schistosomal portal 
hypertension. 
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Objectives 
To determine whether surgical portosystemic shunts have better outcomes compared with 
oesophagogastric devascularisation procedures in the prevention of variceal rebleeding due to 
schistosomal portal hypertension. 
Methods 
Criteria for considering studies for this review 
Types of studies 
Randomised clinical trials (RCTs) were identified in which surgical portosystemic shunts 
were compared with oesophagogastric devascularisation (with or without splenectomy) for 
the prevention of variceal rebleeding in people with hepatosplenic schistosomiasis. For 
assessment of harms, we intended to include quasi-randomised studies and observational 
studies identified during our search for randomised clinical trials. We are aware that this 
approach reduces the risk of overlooking harms. 
Types of participants 
Inclusion 
Participants with hepatosplenic schistosomiasis complicated by variceal bleeding (whether 
first episode or recurrent) were included. 
Exclusion 
Participants with concomitant cirrhosis from any cause or who have had TIPS were excluded. 
Types of interventions 
The following types of surgical shunt interventions were considered: 
1. portacaval shunt (connecting the portal vein and the vena cava); 
2. mesocaval shunt (connecting the mesenteric vein and the vena cava); 
3. central (proximal) splenorenal shunt (connecting proximal splenic vein to left renal 
vein with or without splenopancreatic and gastric disconnection or splenectomy); 
4. distal splenorenal shunt (connecting distal splenic vein to left renal vein with or 
without splenopancreatic and gastric disconnection); 
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5. large-diameter H-graft shunt (16 mm, externally reinforced polytetrafluorethylene 
either as mesocaval or portocaval shunt); 
6. small diameter H-graft shunt (8 mm, externally reinforced polytetrafluorethylene 
either as mesocaval or portacaval shunt). 
Oesophagogastric devascularisation with or without splenectomy, and with or without 
oesophageal transection was considered as the comparator. 
Types of outcome measures 
Primary outcomes 
1. All-cause mortality: 
o immediate (30 days); 
o intermediate (one year); and 
o long-term (five years). 
2. Variceal rebleeding rate (diagnosed clinically by haematemesis, melaena, or blood in 
gastric aspirate, or by endoscopy). 
3. Serious adverse events (procedure-related complications). We used the International 
Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice's 
definition of a serious adverse event (ICH-GCP 1997), that is, any untoward medical 
occurrence that resulted in death, is life threatening, requires hospitalisation or 
prolongation of existing hospitalisation, resulted in persistent or significant disability 
or incapacity, or is a congenital anomaly or birth defect. We considered all other 
adverse events as non-serious. 
4. Quality of life (QOL): We defined QOL as the extent to which a person's usual or 
expected physical, emotional, and social well-being has been affected by the 
intervention (Cella 1995). Since trial authors are likely to use different instrument to 
measure quality of life, the recommendation for choosing a statistical method to 
enhance interpretability (Thorlund 2011b) was used were possible to evaluate quality 
of life estimates in this meta-analysis. 
Secondary outcomes    
1. Number of people who developed encephalopathy, defined by any of the following:  
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a). classical signs detected on physical examination (change in mental status examination in 
association with elevated ammonia, and asterixis);  
b). signs unequivocally described by person's relatives;  
c). psychometric testing; or  
d). electroencephalogram. 
2. Development of new or worsening of pre-existing ascites detected clinically or 
radiologically. 
3. Number of people requiring re-intervention. 
Search methods for identification of studies 
Electronic searches 
We performed electronic searches for relevant trials in the Cochrane Hepato-Biliary Group 
Controlled Trials Register (Gluud 2016 May 2016), Cochrane Central Register of Controlled 
Trials (CENTRAL; 2016, Issue 4), MEDLINE (Ovid SP; 1946 to May 2016), EMBASE 
(Ovid SP; 1974 to May 2016), and Science Citation Index Expanded (Web of Science; 1900 
to May 2016) (Royle 2003). The search strategies and the time spans of the searches are 
listed in Appendix 2. 
Searching other resources 
Reference list of identified studies were hand-searched for further relevant trials. 
Conference/meeting proceedings and abstracts published by International Hepato-Pancreato 
Biliary Association (IHPBA) (1994 to May 2016), the American Association for the Study of 
Liver Diseases (AASLD) (1994 to May 2016), and other relevant organisations were also 
searched. 
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Data collection and analysis 
Selection of studies 
CJE and MB independently applied the inclusion criteria to select relevant studies. Areas of 
disagreement were resolved through discussion. Unpublished data were sort by writing to the 
authors. 
Data extraction and management 
The review authors (CJE and MB) independently extracted data from selected trials using a 
standardised data collection form Appendix 1, which included. 
 Name of first author. 
 The date of trial publication. 
 Country of trial and duration of follow-up. 
 Inclusion and exclusion criteria. 
 Demographic data. 
 Biochemical data. 
 Method of diagnosis of schistosomiasis. 
 Number of participants randomised, number excluded with reasons, and number of 
withdrawals. 
 Methodological quality. 
 Outcomes. 
Assessment of risk of bias in included studies 
Methodological quality was defined as the confidence that the trial design, conduct, analysis, 
and subsequent report have minimised or avoided biases in the intervention comparison 
(Schulz 1995; Moher 1998; Sterne 2002). In order to control for bias (Schulz 1995; Moher 
1998; Kjaergard 2001; Verhagen 2001; Wood 2008; Lundh 2012; Savović 2012a; Savović 
2012b), the risk of bias for included trials were assessed using the following domains as 
recommended in the Cochrane Handbook for Systematic Reviews of interventions (Higgins 
2011) and the Cochrane Hepato-Biliary Group Module (Gluud 2016). Where this information 
has not been provided in the trial report, trial authors were contacted. 
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Random sequence generation 
 Low risk of bias: sequence generation was achieved using computer random number 
generation or a random number table. Drawing lots, coin tossing, shuffling cards or 
envelopes, and throwing dice were adequate if performed by an independent person 
not otherwise involved in the trial. 
 Unclear risk of bias: the method of sequence generation was not specified. 
 High risk of bias: the sequence generation method was not random. These studies 
were only used for the assessments of harms and not for benefits. 
Allocation concealment 
 Low risk of bias: the participant allocations could not have been foreseen in advance 
of, or during, enrolment. Allocation was controlled by a central and independent 
randomisation unit. The allocation sequence was unknown to the investigators (e.g., 
the allocation sequence was hidden in sequentially numbered, opaque, and sealed 
envelopes). 
 Unclear risk of bias: the method used to conceal the allocation was not described so 
that intervention allocations may have been foreseen in advance of, or during, 
enrolment. 
 High risk of bias: the allocation sequence was likely to be known to the investigators 
who assigned the participants. These studies were only used for the assessments of 
harms and not for benefits. 
Blinding of participants and personnel 
 Low risk of bias: blinding was performed adequately, or the assessment of outcomes 
was not likely to be influenced by lack of blinding. 
 Unclear risk of bias: there was insufficient information to assess whether blinding was 
likely to induce bias on the results. 
 High risk of bias: no blinding or incomplete blinding and the assessment of outcomes 
were likely to be influenced by lack of blinding. 
Blinding of outcome assessment 
 Low risk of bias: blinding was performed adequately, or the assessment of outcomes 
was not likely to be influenced by lack of blinding. 
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 Unclear risk of bias: there was insufficient information to assess whether blinding was 
likely to induce bias on the results. 
 High risk of bias: no blinding or incomplete blinding and the assessment of outcomes 
were likely to be influenced by lack of blinding. 
Incomplete outcome data 
 Low risk of bias: missing data were unlikely to make treatment effects depart from 
plausible values. Sufficient methods, such as multiple imputations, were employed to 
handle missing data. 
 Unclear risk of bias: there was insufficient information to assess whether missing data 
in combination with the method used to handle missing data were likely to induce bias 
on the results. 
 High risk of bias: the results were likely to be biased due to missing data. 
Selective outcome reporting 
 Low risk of bias: The original trial protocol is available and all predefined outcomes 
of interest in the review have been reported in the predefined pattern. If the trial 
protocol was obtained from a trial registry (e.g., www.clinicaltrials.gov), and the trial 
was run and published during the years when trial registration was not required, we 
would have scrutinised all publications reporting on the trial to identify the trial 
objectives, if all outcomes specified in the trial objectives are provided in the results 
section of the publication. 
 Unclear risk of bias: not all pre-defined outcomes were reported fully, or it was 
unclear whether data on these outcomes were recorded or not. 
 High risk of bias: one or more pre-defined outcomes were not reported. 
For-profit bias 
 Low risk of bias: the trial appeared to be free of industry sponsorship or other type of 
for-profit support that may manipulate the trial design, conductance, or results of the 
trial. 
 Unclear risk of bias: the trial may or may not be free of for-profit bias as no 
information on clinical trial support or sponsorship was provided. 
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 High risk of bias: the trial was sponsored by industry or received other type of for-
profit support. 
Other bias 
 Low risk of bias: the trial appeared to be free of other bias domains that could put it at 
risk of bias. 
 Unclear risk of bias: the trial may or may not have been free of other domains that 
could put it at risk of bias. 
 High risk of bias: there were other factors in the trial that could put it at risk of bias. 
Trials were classified at low risk of bias if assessed with low risk of bias in all of the above 
domains and as high risk of bias if assessed as unclear or high risk in one or more of the 
above domains. 
Measures of treatment effect    
We measured intervention effects using risk ratios (RR) with 95% confidence interval (CI) 
for dichotomous variables, and continuous variables if identified were measured with a 
standardized mean difference. A pooled estimate of treatment effect was calculated using the 
random-effects model (DerSimonian 1986), and the fixed-effect model (DeMets 1987). In 
case of statistical differences between the two models, we report both results; otherwise, the 
results from the model with the most conservative findings (the analysis with the highest P-
value) was reported (Jakobsen 2014). The degree of heterogeneity between trials was 
measured using the I2 statistic (Higgins 2002; Sterne 2011). 
Unit of analysis issues   
The unit of analysis were the participants recruited into comparison groups of the trials. 
Dealing with missing data   
None of the trials used an intention-to-treat analysis, but we considered the impact of attrition 
bias in our review findings. Where the method of dealing with incomplete data was not clear 
the trial authors were contacted to provide clarification. 
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Assessment of heterogeneity    
Heterogeneity was assessed using the Chi2 test and I2 statistic (Egger 1997; Sterne 2011), and 
the values interpreted as follows: 
 0% to 40%: might not be important; 
 30% to 60%: may represent moderate heterogeneity; 
 50% to 90%: may represent substantial heterogeneity; 
 75% to 100%: represent considerable heterogeneity. 
An I2 value above 50% was considered as significant, and subgroup analyses to investigate 
the possible cause of heterogeneity were attempted where possible. 
Assessment of reporting biases    
No published protocols were found for either trial; however, trial publications included 
outcomes of interest as stated in the method section. A funnel plot could not be drawn to 
assess reporting bias as there were only two trials (Begg 1994; Egger 1997; Harbord 2006). 
Data synthesis    
Recommendations in the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins 2011) and the Cochrane Hepato-Biliary Group Module (Gluud 2016) were followed 
while performing this meta-analysis. Intervention effect was calculated using risk ratio for 
dichotomous outcomes. The statistical packages Review Manager 5 (RevMan 2014) and Trial 
Sequential Analysis (Thorlund 2011a; TSA 2011) were used for data analysis. The Mantel-
Haenszel method was also used for this meta-analysis (Mantel 1959). 
Trial Sequential Analysis 
Cumulative meta-analyses can introduce random errors because of sparse data and repetitive 
analyses; hence trial sequential analysis was used in this review (Thorlund 2011a; TSA 
2011). In an attempt to reduce random errors, the diversity-adjusted required information size 
(i.e., the number of participants needed in a meta-analysis to detect or reject a certain 
intervention effect) was calculated by making the following assumption (Wetterslev 2008): a 
relative risk reduction of 20% or the relative risk reduction observed in the included trials 
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with low risk of bias, a risk of type I error of 5%, a risk of type II error of 20%, and assumed 
diversity present in the meta-analysis (Brok 2008; Wetterslev 2008; Brok 2009; Thorlund 
2009; Wetterslev 2009; Thorlund 2010). A constant continuity correction of 1.0 was applied 
were trials recorded no event as required by trial sequential analysis software. We assumed 
that testing for statistical significance was performed with each new trial added to the trial 
sequential meta-analysis. On the basis of the calculated diversity-adjusted required 
information size, we constructed trial sequential monitoring boundaries. If the test statistics 
crossed the trial sequential monitoring boundary for benefit or harm before the required 
information size was reached, we concluded a statistically significant difference in estimate 
of effect exist. In contrast, if the boundary was not surpassed, we concluded that there is no 
difference in the estimate of effect as the test statistics were below the futility boundary. 
However, where the test statistic crossed the monitoring boundary for futility before the 
required information size was reached, it may not be necessary to continue conducting further 
trials (Wetterslev 2008; Thorlund 2011a). 
 Subgroup analysis and investigation of heterogeneity    
Subgroup analysis was performed to investigate the origin of significant heterogeneity in total 
rebleeding. Further subgroup analyses were not possible because of small sample or 
insufficient comparable groups. A funnel plot was not used as there were an insufficient 
number of trials for this meta-analysis. 
Sensitivity analysis    
Eligibility criteria for included and excluded trials were reviewed and none were found to be 
dubious. Data imputation for this review was reassessed; the results and conclusion were 
determined to be durable. Trial Sequential Analysis was used to reassess the imputed data for 
random errors. 
'Summary of findings' table 
Primary and secondary outcomes are listed in Summary of findings table 1 using GRADEpro 
software (GRADEpro), based on five domains: risk of bias, inconsistency, indirectness, 
imprecision, and risk of publication bias. 
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Assumed risk was determined from the literature. The corresponding risk (and its 95% 
credible interval) was based on the assumed risk in the comparison group and the relative 
effect of the intervention (and it's 95% CI). 
The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) 
Working Group grades of evidence were used: 
 high quality: further research is very unlikely to change our confidence in the estimate 
of effect; 
 moderate quality: further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate; 
 low quality: further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate; 
 very low quality: we are very uncertain about the estimate. 
Results  
Description of studies  
Results of the search    
The database search identified 1846 references; no references were identified from other 
sources. Following exclusion of duplicates, 1144 references were screened for inclusion into 
this review. Seventeen references were selected for full manuscript review of which 12 
studies were excluded with reasons (Characteristics of excluded studies). Five published 
reports of two randomised clinical trials (Da Silva 1992; Raia 1994; Strauss 1999; Gawish 
2000, Conn 1994) met the eligibility criteria and were included for the meta-analysis 
(Characteristics of included studies), according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) (Moher 2009; Figure 1). 
 Included studies   
Two trials (Raia 1994; Gawish 2000) comprising 154 participants were analysed. Raia 1994 
randomised 94 participants into three groups: 32 to proximal (central) splenorenal shunt, 30 
to distal splenorenal shunt, and 32 to devascularisation. The age range of their participants 
was 18 years to 55 years, and 11 participants were excluded from their analysis. The study 
was conducted in Brazil. Gawish 2000 randomised 60 participants equally into two groups: 
distal splenorenal shunt versus devascularisation. The age range of their participants was 23 
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years to 65 years with a mean of 41 years. The participants excluded post randomisation were 
replaced and they conducted their study in Egypt. In both trials liver biopsy was performed to 
confirm features of periportal fibrosis and to exclude cirrhosis. However, Gawish 2000 
included participants classified as Child-Pugh class A and B. This created the impression that 
some participants could be cirrhotic. The trial authors were contacted for clarity, but it 
appears that this could be problem of external validity (Characteristics of included studies). 
 Excluded studies     
Twelve trials were excluded with reasons following the review of the full-text articles. Nine 
were excluded as they included cirrhotic participants. Two other articles were duplicate 
publications of excluded trials, while one (de Cleva 2007) is a quasi-randomised study which 
evaluated haemodynamic parameters before and after interventions in hepatosplenic 
schistosomiasis. This study was excluded because harms of intervention were not reported. 
(Characteristics of excluded studies). 
Risk of bias in included studies   
Methodological qualities in all predefined domains were evaluated; both included trials were 
at high risk of bias as more than one domain was either unclear or high risk (Figure 2; Figure 
3). 
Allocation (selection bias)   
Allocation sequence was generated using random number table by (Raia 1994) but it was not 
clear the method used by (Gawish 2000). However in both trials sealed envelopes were used 
to conceal allocations and therefore are considered at low risk of selection bias. 
Blinding (performance bias and detection bias)   
It was not clear if blinding was used in either trial. However, blinding clinicians and trial 
participants for surgical procedures is difficult to impossible. Therefore, we considered this to 
have an unclear risk of performance and detection bias. 
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Incomplete outcome data (attrition bias)   
Neither trial employed an intention-to-treat method in their analysis. Gawish 2000 excluded 
all participants whose procedure were regarded as not properly done and replaced them with 
others. The method of selection of neither these replacement participants nor the adverse 
events in the participants who were replaced was not clearly documented in their publication. 
The author was contacted to clarify this discrepancy but did not provide satisfactory 
explanation. Raia 1994 excluded all participants with missing data. Therefore, we assessed 
both trials as high risk of attrition bias. 
Selective reporting (reporting bias)   
Neither trial had published report of their protocol. However, it appears that all predefined 
outcomes in their method section were reported, but all potential adverse events were not 
reported. Therefore, we assessed both trials as unclear risk of reporting bias. 
Other potential sources of bias   
The impact of industry sponsorship was considered; however, it was unclear how Gawish 
2000 funded their trial. Raia 1994 reported an institutional grant as source of funding. This 
was assessed as low risk of bias. 
Effects of interventions    
All shunts (proximal and distal splenorenal shunt) versus devascularisation 
A total of 143 participants from two trials (Raia 1994; Gawish 2000) received one of three 
types of surgical procedures: 28 to proximal splenorenal shunt, 57 to distal splenorenal shunt, 
and 58 to oesophagogastric devascularisation with splenectomy. Raia 1994 randomised their 
participants into three surgical groups: proximal splenorenal shunt, distal splenorenal shunt 
and devascularisation, but Gawish 2000 randomised their participants into two groups: distal 
splenorenal shunt and devascularisation. We determined that a meta-analysis of 'all shunt' 
compared with devascularisation is not possible as both trials are not similar with regards to 
this comparison hence the occurrence of significant heterogeneity, I2 =50% in the estimate of 
all-cause mortality and I2 =78% in the estimate of total rebleeding rate (Analysis 1.1; 
Analysis 1.2).  
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Distal splenorenal shunt versus devascularisation  
Both trials (Raia 1994; Gawish 2000) included data from 115 participants who received two 
types of procedures, distal splenorenal shunt or devascularisation. Raia 1994 reported their 
outcomes at different time points, two years, and ten years. Gawish 2000 reported five year 
outcomes. 
All-cause mortality 
There were a total of seven deaths out of 115 participants, four deaths occurred in the DSRS 
group versus three in the devascularisation group. The main cause of death was rebleeding in 
four out of seven deaths. There was no significant difference in all-cause mortality (RR 1.40, 
95% CI 0.32 to 6.15) P = 0.66, I2 = 3%; Analysis 2.1). 
Variceal rebleeding 
Both trials reported total rebleeding rate, and subgrouped participants into sources of 
rebleeding. This included two variceal, three non-variceal and two undetermined bleeders in 
the DSRS group; nine variceal and five non-variceal bleeders in devascularisation group. One 
variceal rebleed in DSRS group in Gawish 2000 was caused by shunt occlusion. There was 
no statistically significant difference for total rebleeding rate; however, substantial 
heterogeneity using random-effects meta-analysis was noted (RR 0.43, 95% CI 0.05 to 3.71, 
P = 0.44, I2 = 74%; Analysis 2.2). 
The meta-analysis of rebleeding sources (variceal or non-variceal) showed that the 
heterogeneity had disappeared. Random-effects meta-analysis of variceal rebleeding showed 
significantly less rebleeding with DSRS compared with devascularisation (RR 0.23, 95% CI 
0.05 to 1.01, P = 0.05, I2 = 0%). This was similar with fixed-effect model (RR 0.23, 95% CI 
0.05 to 1.00, P = 0.05, I2 = 0%; Analysis 2.3). The event rate in DSRS of two out of 57 
compared to nine out of 58 in devascularisation gave a NNTB of 8. 
However, Trial Sequential Analysis diversity-adjusted calculated required information size of 
188 was not reached, and the cumulative Z-curve did not cross the trial sequential monitoring 
boundaries or the futility boundary. The trial sequential pooled effect is 0.23 with alpha-
spending adjusted 95% confidence interval (CI) 0.03 to 1.69 (Figure 4). 
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Serious adverse events 
The serious adverse events reported are shown in, Serious adverse event table. There was 
heterogeneity in the pattern of reporting and most events were procedure-specific. None of 
the studies reported on all types of serious adverse events, for example anastomotic leak and 
surgical site infections were not reported. The confidence interval for the reported serious 
adverse events was calculated using the Wilson method (Wilson 1927). 
Quality of life 
Neither trial reported on quality of life. 
Encephalopathy 
Seven out of 57 participant in DSRS group versus none in the devascularisation group 
developed post procedure encephalopathy. This difference is statistically significant using a 
random-effects meta-analysis (RR 8.10, 95% CI 1.04, to 62.83) P = 0.05, I2 = 0%; Analysis 
2.4). The same effect was observed using a fixed-effect meta-analysis (RR 8.15, 95% CI 
1.05, to 63.07) P= 0.04, I2 = 0%). Trial Sequential Analysis was used to compute diversity 
adjusted required information size of 157, based on assumed type I error of 5%, and type II 
error of 20%. The cumulative Z-curve did not cross the sequential monitoring boundary and 
the required information size was not reached. In addition futility boundary was not 
surpassed. The Trial sequential Analysis pooled effect is 8.1 and alpha-spending adjusted 
95% CI 0.68 to 96.96 (Figure 5).  
Re-intervention 
One out of 30 participants (3%, 95% CI (1% to 17%) in the DSRS group required a re-
intervention due to rebleeding caused by shunt occlusion (Gawish 2000). 
Proximal splenorenal shunt versus distal splenorenal shunt 
A meta-analysis of PSRS compared with DSRS could not be performed because only one 
trial (Raia 1994) could be identified. However the result from this study shows all-cause 
mortality (RR 2.89, 95% CI 1.06 to 7.87; Analysis 3.1), and encephalopathy (RR 2.65, 95% 
CI 0.96 to 7.32; Analysis 3.4), following PSRS is statistically significant higher than after 
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DSRS. There was no statistical difference in rate of variceal rebleeding (RR 2.89, 95% CI 
0.32 to 26.12; Analysis 3.3), intravascular haemolysis (RR 0.55, 95% CI 0.28 to 1.10; 
Analysis 3.5), or shunt occlusion (RR 1.65, 95% CI 0.35 to 7.71; Analysis 3.6). 
Discussion   
Summary of main results    
This systematic review was designed to compare all portosystemic shunts versus 
devascularisation in the prevention of variceal rebleeding due to hepatosplenic 
schistosomiasis. We identified only two randomised clinical trials which compared two types 
of procedures, namely distal splenorenal shunt and devascularisation with splenectomy 
suitable for this review. Hence the results of this comparison are presented in this review. 
The meta-analysis demonstrated no mortality difference between both procedures based on 
very low quality evidence. 
The risk of variceal rebleeding post procedure was more common with devascularisation 
compared to DSRS. There could be several reasons for the higher rate of rebleeding 
associated with devascularisation. Firstly, the various modifications of this procedure could 
result in incomplete devascularisation (Hassab 1998; Orozco 1998). Secondily, a high rate of 
portal vein thrombosis could follow splenectomy (Eguchi 1991); and lastly, recanalization of 
varices due to maintenance of azygos blood flow after devascularisation could play a role 
(Vons 1996). However, Trial Sequential Analysis showed no firm evidence to accept a 
significant difference in variceal rebleeding rate, but more trials are required in order to reach 
the required information size before a firm conclusion is drawn.  
 Encephlopathy was significantly more common following DSRS. This could be explained 
that a proportion of portal venous blood flow was diverted into the systemic circulation, thus 
bypassing the detoxifying liver as opposed to devascularisation were effective hepatic blood 
flow is maintained ( Raia 1991; Vons 1996; Pereira 2013). A reversal of hepatopetal flow to 
hepatofugal flow which has been documented in cirrhotics treated with DSRS could play a 
role but none of the trials demonstrated this (Lacy 1992). Trial sequential analysis showed no 
firm evidence to accept the difference in encephalopathy because quality of evidence is very 
low due to imprecision, high risk of bias, and publication bias. Raia 1994 described a grading 
37 
 
system for encephalopathy in their method but did not grade their findings. Gawish 2000 
reported a hepatopetal blood flow in all their participants, and all cases of encephalopathy 
were described as mild because they all resolved promptly with dietary modification. A meta-
analysis of encephalopathy in PSRS compared with DSRS could not be undertaken as there 
were insufficient RCTs. Raia 1994 compared proximal splenorenal shunt versus distal 
splenorenal shunt and reported a significant difference in rate of encephalopathy in favour of 
DSRS (RR 2.65, 95% CI 0.96 to 7.32; Analysis 3.4). 
Serious adverse events could not be analysed as an outcome; however, we report the 
individual trial adverse events in, (Serious adverse event table). The rate of portal vein 
thrombosis in Gawish 2000 is higher than published data (Eguchi 1991), which raises 
questions as the only modality for diagnosis as reported by the authors was use of duplex 
ultrasonography. These data are skewed by the number of asymptomatic partial portal 
thrombosis of 17 out of 30 participants compared to total portal vein thrombosis of one out of 
30 participants, (Serious adverse events table). Infectious complications specifically 
overwhelming post splenectomy infection (OPSI) is a concern when devascularisation is 
associated with splenectomy. Both studies did not provide data for this adverse event; 
however evidence suggests a preservation of cellular and humoral immunity in hepatosplenic 
schistosomiasis that is protective against OPSI (Ma 1993; Ferreira 2007). 
Quality of life following any healthcare intervention determines how patients accept such 
interventions, and has implication for healthcare policy decision-making (Vianello 2011; 
Roszell 2013). None of the studies measured this outcome and this adds to the limitations of 
this review. 
Overall completeness and applicability of evidence   
The two trials selected for this review consisted of a small number of participants; hence 
estimates of intervention effects varied between studies and were largely small. Neither of the 
trials evaluated all the predefined outcomes of our protocol; for example, we could not 
evaluate for quality of life and all adverse events. This has implication for acceptance of 
healthcare interventions. Although the correct participants were recruited, not all 
interventions were studied by both trials making comparison impossible. We intended to 
include quasi-randomised studies and observational studies for the assessment of harms of 
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interventions but no such studies that evaluated adverse events were found. This is limitation 
of this meta-analysis because of the risk of overlooking harms of interventions. 
We could not investigate for heterogeneity using funnels plot because of inadequate number 
of trials. Subgroup analyses were not possible due to the small sample sizes. Therefore, 
available evidence is inconsistent, imprecise and of very low quality to adequately address 
the review question. Current guideline recommend endoscopic treatment as first-line for the 
prevention of variceal bleeding and surgery as rescue treatment when the former fails (de 
Franchis 2010; Sarin 2010). Nonetheless controversy remains as to what the best surgical 
procedure is. Trial sequential analysis demonstrated that more trials are needed to achieve the 
required information size in order to attain the true intervention effect for most outcomes. 
Strauss 1999 studied 73 participant subsets of (Raia 1994) trial for changes in variceal size 
post intervention. Clinical assessment of variceal size is highly subjective. Moreover there 
was no correlation of variceal size to rebleeding in this study. Therefore this outcome was not 
included in this meta-analysis. 
Quality of the evidence    
The two trials selected for this review are at high risk of bias. Such trials have the potential to 
give false intervention effect estimates due to their inadequate design (Schulz 1995; Moher 
1998; Kjaergard 2001; Verhagen 2001; Wood 2008; Lundh 2012; Savović 2012a; Savović 
2012b). Both trials randomised 154 participants to three types of surgical procedure but only 
the data of 115 participants who received two types of surgical procedures (distal splenorenal 
shunt versus devascularisation) were available for the final analysis. 
The quality of evidence for all-cause mortality, variceal rebleeding and encephalopathy is 
downgraded three levels to very low quality for risk of bias based on the over-all assessment, 
imprecision (very large confidence interval, few participants) heterogeneity; and reporting 
bias (few publications report the outcome). 
There is significant heterogeneity between the trials. We performed a meta-analysisof 
variceal-rebleeding despite the small number of events. It is possible that the calculated effect 
size could have overestimated the benefit or underestimated the harm of the interventions. 
We applied Trial Sequential Analysis to evaluate for random error (Wetterslev 2008). It 
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appears that further trials are needed to draw a firm conclusion of an intervention effect. We 
could not perform a meta-analysis of PSRS versus DSRS, nor PSRS versus devascularisation 
due to insufficient number of trials. Moreover the impact of publication bias on this review 
could not be investigated using funnels plot because the number of trials required should be 
ten or more. This is also an important limitation of this review. 
Potential biases in the review process   
Analysis of the included studies (Raia 1994; Gawish 2000) showed that one trial (Raia 1994) 
used a random number table to generate sequence but the method used by Gawish 2000 was 
unclear. Both trials used sealed envelopes for allocation concealment. Neither of the trials 
was blinded to personnel, nor participants and outcome assessors, but we are not convinced 
that this could have introduced bias, because all were objective outcomes. There was risk of 
attrition bias in both trials as one study excluded incomplete data in their computation, while 
the other replaced all participants with incomplete data using a method that was unclear. 
Neither trials published protocol; one trial was funded by institutional grant while the source 
of funding was unclear for the other. We conclude that both trials were at high risk of bias 
based on the protocol predefined domains. 
Sensitivity analysis was performed to evaluate the search process, method for selection of 
included studies and data extraction by the review authors. We also reviewed the decision 
made to exclude certain studies or resolve disagreement for potential sources of bias but 
found none. 
Agreements and disagreements with other studies or reviews   
To date there has been no systematic review that has compared surgical portosystemic shunts 
to devascularisation with or without splenectomy for prevention of variceal rebleeding due to 
hepatosplenic schistosomiasis. This review was designed to provide evidence for the best 
surgical procedure in terms of efficacy and adverse events. We found two surgical procedures 
(DSRS versus devascularisation) in two trials that fulfilled the requirements of our review 
protocol for this meta-analysis. 
Yin 2013 published a meta-analysis that compared four types of interventions: non-selective 
shunt, selective shunt, devascularisation, and a procedure that combines shunt and 
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devascularisation. Their participants included cirrhotics and non-cirrhotics. The finding of 
their review is in agreement with this meta-analysis. However, they showed that the 
combined procedure was associated with significantly less rebleeding. Moreover, the 
encephalopathy rate for the combined procedure was comparable to that of devascularisation. 
They recommended the combined procedure in all type of variceal bleeding. Their review has 
similar limitations as the present review and they have not reported the adverse events 
associated with the combined procedure but one would expect it will be higher than the 
isolated procedures. 
Zong 2015 published a meta-analysis of eleven studies comparing devascularisation to 
surgical shunts in both cirrhotic and non-cirrhotic portal hypertension. The conclusion of that 
meta-analysis agrees with our review. It would seem that people with hepatosplenic 
schistosomiasis behave the same as cirrhotics. This could be due to similar participant sets in 
both cirrhotic and non-cirrhotics. The current practice in the era of TIPS, and liver 
transplantation demand that these surgical procedures are performed in well-compensated 
cirrhotics (Gur 2014). 
Authors' conclusions   
Implications for practice   
Given that available body of evidence is very low quality, we could not determine an overall 
outcome benefit or harm of DSRS compared with devascularisation in prevention of variceal 
rebleeding due to hepatosplenic schistosomiasis. There appears to be a tendency to less 
episodes of variceal rebleeding following a distal splenorenal shunt, and decreased incidence 
of encephalopathy following devascularisation. 
Implications for research   
Future randomised clinical trials evaluating the outcomes of surgical portosystemic shunts 
such as H-graft shunts and the DSRS compared with devascularisation with or without 
splenectomy and with or without oesophageal transection are required. In order to achieve 
sufficient statistical power, such trials should be conducted in multiple institutions located in 
schistosomiasis endemic areas. All outcomes of interests such as all-cause mortality, variceal 
rebleeding, serious adverse events, encephalopathy, cost, haemodynamic changes, and quality 
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of life should be evaluated. These trials should have their protocol drafted according to the 
SPIRIT statement (Chan 2013) and their reporting according to the CONSORT statement 
(Schulz 2010). 
Differences between protocol and review   
The title of the review was changed into: "Surgical portosystemic shunts versus 
devascularisation procedure for prevention of variceal rebleeding due to hepatosplenic 
schistosomiasis". This has been done to reflect the objective of the review as highlighted by 
the editors. 
Contributions of authors   
CJE drafted the review. 
CJE and MB conducted the search and data extraction. 
CJE entered the data into Revman, data analysis and interpretation. 
CJE and MB discussed and approved this review. 
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Trial sequential graph (encephalopathy) 
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Forest Plot: Analysis 
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Section 4: Annexure - Proposal 
4.1 Background 
Oesophagogastric varices occur in patients that suffer from portal hypertension either as 
sequelae of liver cirrhosis or with presinusoidal causes such as schistosomiasis. In portal 
hypertension there is a pathological increase in the portocaval pressure gradient (Sanyal et al. 
2008) resulting in the development of varices, encephalopathy, hypersplenism and ascites 
(Goff, 1993). Variceal bleeding is a significant cause of death in patients with portal 
hypertension (approximately 50% from the first bleed in liver cirrhosis) (Graham & Smith, 
1981; de Dombal, et al. 1986). In survivors of the first episode, recurrent bleeding is not 
uncommon and the risk of rebleeding is greatest during the first thirty days following the 
initial bleed (Smith & Graham, 1982).   
Schistosomiasis is a parasitic disease that is endemic in poor communities with inadequate 
sanitation and lack of access to portable water (Steinmann et al, 2006). The World Health 
Organisation estimates the total number of people infected worldwide as over 200 million. 
More than 90% of these live in Africa (WHO, 2014). The hepatosplenic form of the disease is 
caused by two species of the blood fluke Schistosoma, namely S. mansoni found 
predominantly in Africa, Arabia and South America, and S. japonicum found in South-East 
Asia, especially mainland China. The adult worms of both species inhabit the mesenteric 
veins where they mate and deposit eggs. A granulomatous inflammatory reaction to the 
trapped eggs in portal vein radicles results in portal fibrosis (Symmer’s (clay) pipe stem 
fibrosis) (Symmers, 1904). This fibrosis results in the development of presinusoidal portal 
hypertension (Ross et al. 2002). 
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Portal Hypertension is defined as a portal venous pressure gradient greater than 8mmHg and 
clinically obvious variceal bleeding occur when the pressure gradient exceeds 12mmHg 
(Sanyal et al. 2008).   
The algorithm for the treatment of acutely bleeding varices in both cirrhotic and non-cirrhotic 
portal hypertension is the same and includes a combination of pharmacologic and endoscopic 
therapy, radiological shunt such as transjugular intrahepatic portosystemic shunt (TIPS) and 
surgery (either a shunt or a devascularization procedure). In acute variceal bleeding early 
aggressive resuscitation is recommended. A vasoactive agent infusion and endoscopic 
therapy are the primary treatment measures (de Franchis, 2010; Gonzalez et al. 2008). 
However recurrent bleeding despite these measures occurs in 40-60% of patients (Snady, 
1987) and secondary prophylaxis are therefore imperative (de Franchis, 2010; Rikkers et al. 
1992; Whipple, 1945). The risk of rebleeding without secondary prophylaxis approaches 70% 
during the first two years (D’Amico et al. 1995) with the greatest risk occuring within the 
first few days following a bleed (Smith & Graham, 1982).   
In the era of radiological shunt (TIPS), the use of surgical shunts and devascularization 
procedures have decreased as TIPS offers a minimally invasive alternative and serve as a 
bridge to liver transplantation (Boyer & Haskal, 2010; John et al. 1996). Nonetheless, only 
3% to 14% of eligible cirrhotic patients eventually receive liver transplant (Rosemurgy et al. 
2012; Toomey et al. 2013). The long term patency of TIPS as well as long term survival rates 
are less than surgical shunts (Orloff, 2014; Rosemurgy et al. 1996). The 5-year patency and 
survival rate for a surgical shunt is 97% and 68% respectively (Gur et al.  2014). The median 
survival after TIPS is 26months compared to 52months after H-graft portocaval shunt 
(HGPCS) (Rosemurgy et al. 2012). The early shunt occlusion occurred within 30days in 17% 
of patient after TIPS compared to 9% after surgical shunt (Rosemurgy et al. 1996).  However 
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this data is only valid in cirrhotic patients. However, there is no literature to my knowledge 
supporting the use of TIPS in SPH (Eesa & Cark, 2011). 
In SPH hepatic venous pressure and hepatic function are largely preserved if there are no 
other concomitant liver diseases such as viral hepatitis infection (Denie et al. 1996; Bica et 
al. 2000). There is firm evidence in support of surgical shunts for portal decompression in 
SPH as these subgroups of patients are young with preserved liver function (Gur et al. 2014; 
Ferraz et al. 2001; Spina et al. 1992; Henderson, 1988). 
The aim of surgery is to reduce the high pressure in the portal circulation. This is achieved by 
diverting portal venous blood into the systemic circulation. Generally, two types of 
procedures are described, shunt and devascularization (Da Silva & Carrilho, 1992). Surgical 
shunts are traditionally divided into selective and non-selective types. When compared to 
selective shunts, the non-selective shunts divert all portal blood away from the liver into the 
systemic circulation resulting in reduction in effective hepatic blood flow. The risk of 
encephalopathy after non-selective shunt in SPH approach 39%, hence selective shunts are 
advocated (Andersson & Chung, 2007; Raia et al. 1994). Perioperative mortality following 
shunt procedures is 6%, with 5-year survival rate of 68% to 75% (Gur et al, 2014;Orloff et al. 
2009;Rikker et al. 1992;Paquet et al. 1989). 
On the other hand, devascularization procedure have higher rebleeding rate of 7% to 40% 
(Johnson et al. 2006; Henderson, 1988), compared to surgical shunt with rates of 5% to11% 
depending on the type of shunt (Rikkers, 1998). Also the risk of encephalopathy with 
devascularization is rare and overall operative mortality higher at 13% (Rikkers, 1998; Qazi 
et al, 2006; Suigura & Futagawa, 1984). Hence, devascularization procedures have higher 
mortality and a disappointing long term outcome because of high rate of rebleeding compared 
to selective surgical shunt. 
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To date no meta-analysis or systematic review has compared surgical porto-systemic shunts 
to devascularisation procedures in control of acute or recurrent variceal bleeding due to SPH. 
Therefore in this review I will compare surgical porto-systemic shunts to oesophagogastric 
devascularization procedures in the treatment of variceal bleeding as a result of SPH. 
Description of the intervention   
Portosystemic shunts are surgically created conduits that divert part or all of portal venous 
blood flow away from the liver into the systemic circulation. This conduit may be autogenous 
graft or polytetrafluoroethylene (PTFE) prosthesis. 
Commonly created surgical portosystemic shunts include the non-selective 16mm H-graft 
shunt and the selective DSRS (Warren et al. 1967). The H-shunt is created between the portal 
vein and the inferior vena cava using an 8mm to 16mm ringed PTFE prosthesis. The PTFE 
graft is nonexpansible and by diminishing its diameter from 16mm to 8mm a partial portal 
decompression is achieved (Sarfeh et al, 1986; Sarfeh et al, 1994). 
The distal splenorenal shunt is created by anastomosing the distal splenic vein to the left renal 
vein and disconnecting the splenopancreatic and gastric venous connections to the portal 
system while preserving portal venous blood flow and hepatic function. 
Oesophagogastric devascularization includes perihiatal devascularisation of the distal 4cm to 
6 cm of abdominal esophagus and ligation of the short and left gastric vessels. This is 
combined with oesophageal transection and splenectomy (OGDS) (Sugiura & Futagawa, 
1972) or without splenectomy 
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OBJECTIVE 
To determine whether or not surgical portosystemic shunts have better outcomes compared to 
oesophago-gastric devascularisation procedures in the management of variceal bleeding 
resulting from SPH. 
 
AIMS 
To identify all RCTs where surgical portosystemic shunts have been compared to oesophago-
gastric devascularisation with or without splenectomy. Controlled clinical trials (CCTs, i.e., 
trials employing quasi/pseudo-randomisation (e.g. alternate allocation)) (published and 
unpublished) identified during the search for randomised trials will be considered for 
evidence of harmful effect of the intervention 
 
M E T H O D S 
Inclusion criteria 
Patients with hepatobiliary-splenic schistosomiasis complicated by variceal bleeding whether 
first episode or recurrent that undergo a surgical shunt or devascularisation procedure are 
eligible for inclusion. 
Exclusion criteria 
Patients with concomitant cirrhosis from any cause or who have had TIPS will be excluded. 
Types of interventions 
All types of surgical shunts:  
 Portacaval shunt (connecting the portal vein and the vena cava) 
 Mesocaval shunt(connecting the mesenteric vein and the vena cava)  
 Central splenorenal shunt (CSRS)(connecting splenic vein to proximal left renal vein) 
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 Distal splenorenal shunt ( connecting splenic vein to distal left renal vein with or 
without spleno-pancreatic venous disconnection)  
 The large diameter H-graft shunt (16mm, externally reinforced polytetraflouethylene 
(PTFE) either as mesocaval or portocaval shunt).Small diameter H-graft shunt (8 mm, 
externally reinforced polytetrafluoroethylene(PTFE) either as mesocaval or portacaval 
shunt) 
Oesophago-gastric devascularisation with or without splenectomy 
 
Types of outcome measures 
Primary:     
1. Procedure related mortality 
 
2. Variceal rebleed rate  (diagnosed clinically by haematemesis, melena, or blood in 
gastric aspirate or by endoscopy) 
 
3. Adverse events (AE) (procedure related complication) will be defined as any 
unfavourable and unintended symptoms, signs, abnormal laboratory results, and 
disease resulting from the surgical procedure (ICH-GCP, 2001). Adverse event will 
be considered as 
a. Acute, if developing within 30 days of the procedure. 
b. Chronic, if developing after 30 days following the procedure. 
4. Quality of life. 
 
Secondary:  
1. All-cause mortality 
a. Immediate (30 days) 
b. Intermediate (one year) 
c. Long-term (five years). 
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2. Number of patients developing encephalopathy which is defined as: 
a. Classical signs found on physical examination    
b. Signs unequivocally described by patient’s relatives 
c. Psychometric testing 
d. Electroencephalogram. 
3. Development of new or worsening of pre-existing ascites detected clinically or 
radiologically 
4. Number of patients requiring a re-intervention 
 
Subgroup analysis:  
1. Type of surgical shunt compared to devascularisation procedure 
2. Trials with low risk of bias compared to trials with high risk of bias 
 
Search methods for identification of studies 
I will perform electronic search for relevant trials in the Cochrane Hepato-Biliary Group 
Controlled Trials Register (Gluud et al. 2012); the Cochrane Central Register of Controlled 
Trials (CENTRAL) in the Cochrane Library; MEDLINE; EMBASE; and Science Citation 
Index Expanded (Royle & Milne, 2003). 
The preliminary strategies for the search and the proposed time span is given in Appendix 2 
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Additional searches 
Journal containing more than one relevant trial will be hand searched provided it has not been 
hand searched already. Reference list of identified trials will be investigated. 
Conference/meeting proceedings and abstracts of the following organizations, International 
Hepato-Pancreato Biliary Association (IHPBA) (1994-2013) and the American Association 
for the Study of Liver Diseases (AASLD) (1994-2013) will be searched. 
 
Data collection and analysis: 
Selection of studies: 
Two reviewers (myself (CJ) and my supervisor (MB)) will select studies based on the 
inclusion criteria. CJ will develop the search strategy. CJ and MB will perform the searches 
independently. Areas of disagreement will be resolved by discussion. Initially all identified 
trials will be entered in a trial register. Data will be independently extracted from reports by 
CJ and MB. CJ will validate the data. Unpublished data will be sought by writing to the 
authors. 
 
Data extraction and management 
I will use the statistical software RevMan 5, 3 provided by the Cochrane collaboration 
(RevMan, 2012) and also the trial sequential analysis (Thorlund et al. 2011) to analyse my 
data. Recommendations contained in the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins & Green, 2011) and the Cochrane Hepato-Biliary Group Module 
(Gluud et al. 2013) will be used to perform this meta-analysis. 
The following data will be collected and recorded in a data extraction form (Appendix 1). 
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Number of patients evaluated for the study and number excluded. 
For each included trial and for each treatment group data collected would be as follows: 
Distribution of age of patients. 
Number of patients randomised. 
Distribution of time from bleeding episode to randomisation. 
Distribution of Child’s criteria (proportion in each category) (Child & Turcotte, 1964). 
Results of biochemical liver function tests. 
 
The following data will be sought post randomisation: 
Mortality at 30 days, one year, and five years. 
Incidence of rebleeding. 
Incidence of encephalopathy. 
Result of biochemical liver function tests. 
Shunt patency. 
Prograde hepatic flow following selective shunt and devascularization 
Adverse events (Procedure related complications). 
Total length of hospital stay during post-operative period. 
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Assessment of risk of bias in included studies   
In order to eliminate bias due to trials with poor design quality (Schulz et al. 1995; Moher et 
al. 1998; Verhagen et al. 2001; Kjaergard et al. 2001), I will assess the risk of bias in 
included trial using the guideline provided in the Cochrane Handbook for Systematic Reviews 
of Interventions (Higgins et al. 2011) and the Cochrane Hepato-Biliary Group Module (Gluud 
et al. 2012) under the following domains:  
Allocation sequence generation 
Allocation concealment 
Blinding of participants, personnel, and outcome assessors 
Incomplete outcome data 
Selective outcome reporting 
For-profit bias 
Trials that have been assessed as low risk in all of the above domains will be regarded at low 
risk of bias. Trials that are deficient in one or more of the specified domains will be 
considered at high risk of bias (Lundh et al. 2012; Higgin & Green, 2011; Kjaergard et al. 
2001). 
Where the required information for bias assessment has not been provided in the trial report, I 
will write to the authors to provide it. 
Measures of treatment effect   
I will measure treatment effect using the relative risk with 95% confidence interval (CI) for 
dichotomous variable, and the standardized mean difference with 95% CI for continuous 
variables. I will conduct a pooled estimate of effect using the random effect model 
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(DerSimonian & Laird, 1986), and the fixed-effect model (Demets, 1987). In case of 
discrepancy between the two models I will report both results; otherwise, I will use only one 
meta-analysis model with the highest P-value to report on the result of intervention effect. I 
will measure the degree of heterogeneity between trials using I2 statistic (Higgin & 
Thompson, 2002; Sterne et al. 2011). 
Unit of analysis issues   
The unit of analysis will be the patients recruited into the trials. 
Dealing with missing data   
All analyses will be performed according to the intention-to-treat method, i.e. all randomised 
patients will be included in the analysis. Where there are missing data I will contact the 
authors to provide the information. Where I do not receive a reply from the authors I will 
consider the patients with missing data as treatment failures. I will analyse the impact of the 
missing data on the review finding in the discussion section. 
Assessment of heterogeneity   
I will assess heterogeneity by use of Chi-squared test and I2 statistic. (Sterne et al. 2011, 
Egger 1997) 
The calculated I2 values will be interpreted as follows: 
1. 0 to 40%: might not be important 
2. 30 to 60%: may represent moderate heterogeneity 
3. 50 to 90%: may represent substantial heterogeneity 
4. 75 to 100%: represent considerable heterogeneity 
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An I2 value above 50% will be considered as significant, and I will investigate the possible 
cause of heterogeneity by performing sensitivity analysis. I will consider any plausible cause 
of heterogeneity in the discussion. 
Assessment of reporting biases   
I will explore for reporting bias in included trial using a funnel plot. I will determine if there 
is an association between treatment effect and study size by visual inspection of the funnel 
plot. A test of asymmetry will be conducted if I find at least 10 studies for analysis (Higgins 
& Green, 2011). Two tests will be used to assess funnel plot asymmetry, the adjusted rank 
correlation test (Begg & Mazumdar, 1994) and regression asymmetry test (Egger et al. 1997). 
Data synthesis   
The recommendations contained in the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins et al. 2011) and the Cochrane Hepato-Biliary Group Module (Gluud et 
al. 2012) will be followed in this meta-analysis. The intervention effect will be calculated 
using relative risk for dichotomous outcome, and standardised mean difference for 
continuous outcome. The statistical package RevMan 5.2 (RevMan, 2012) will be used for 
the analysis and the Mantel-Haenzel method will be used for the meta-analysis (Mantel, 
1959).  
Trial Sequential Analysis 
Cumulative meta-analysis can introduce random error because of repetitive analysis of sparse 
data, so trial sequential analysis will be applied in this meta-analysis. In order to reduce 
random error, I will calculate the required information size( (i.e., the number of participants 
needed in a meta-analysis to accept or reject a certain intervention effect) (Watterslev et al. 
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2008), by making the following assumption: a relative risk reduction (RRR) of 20%,  or RRR 
observed in the included trials with low risk of bias; a risk of type I error of 5%; a risk of type 
II error of 20%, and assumed heterogeneity or diversity present in the meta-analysis 
(Thorlund et al. 2011; Watterslev et al. 2008). 
Subgroup analysis and investigation of heterogeneity   
I will perform sub-group analyses to compare intervention effect in trials of total and 
selective shunts versus devascularization; trials with high risk of bias compared to those with 
low risk of bias. The data generated will further be stratified using Child’s criteria (Child’s 
classification provides objective assessment of hepatic function and prognosis (Child & 
Turcotte, 1964)). In case a study has more than two arms, then data will be extracted only 
from the arms which correspond to the treatment options being considered in this study. 
Sensitivity analysis   
A sensitivity analysis will be performed at the end of the review to assess whether the review 
findings are robust to the decisions made during the review process. This will involve 
assessment of the search method for the included trials, exclusion criteria, the type of data 
analysed, the process of data analysis, and the measure of intervention outcomes. 
Summary of finding table 
I will summarise the evidence from all outcomes in a summary of findings table using 
GRADEpro software (GRADEpro), based on five domains namely: the risk of bias, 
inconsistency, indirectness, imprecision and publication bias 
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Summary of statistical Analysis 
1 Measure of intervention 
effect 
 
Relative risk for dichotomous outcome and  
standardised mean difference for continous outcome at 
95% CI.  
2 Assessment of 
Heterogeneity 
 
Chi-squared test and I2 statistic. I2  > 50% Significant 
 
3 Assessment of reporting 
bias 
 
Funnel plot  using the adjusted rank correlation test and 
regression asymmetry test 
 
4 Trial sequential analysis 
 
Assume RRR 20%, Type I error 5%, and type II error 
20%. 
 
5 Statistical significance P≤ 0.05 
 
6 Meta-analysis models Random and fixed-effects. 
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Timing 
Process Jun July Aug Sep Oct Nov Dec Jan 
Project idea X        
Literature Review X X       
Preparing protocol  X X      
Protocol deadline   20/8/14      
Protocol Assessment    10/9/14     
Ethics application  31/7/14       
Collecting data    X X X   
Data analysis      X X  
Writing up-report      X X  
Report submission        X 
Writing up- paper        X 
 
 
 
 
 
 
 
 
94 
 
Section 5 
Appendices: 1 
 
 
Data Extraction Form 
Review title: Surgical portosystemic shunts versus devascularisation procedures for 
prevention of variceal rebleeding due to hepatosplenic schistosomiasis 
Review authors: 1. Chikwendu J Ede; 2. Martin Brand 
Date: 
Study title: 
First author Journal/Conference Proceedings Date of Publication 
 
 
  
Contact address first author: 
Email address first author: 
Source of sponsorship: 
 
Study eligibility 
 
RCT Relevant participants Relevant 
interventions 
Relevant outcomes 
 
Yes / No / Unclear 
 
Yes / No / Unclear 
 
Yes / No / Unclear 
 
Yes / No* / Unclear 
 
 
(* Possible selective reporting bias. Awaiting assessment until clarified with trial authors.)  
  
Inclusion criteria: 
 
 
Exclusion criteria: 
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Participant characteristics 
 
 
 
PSRS= non-selective proximal portosystemic shunt       DSRS= Selective distal splenorenal 
shunt 
OGD = Oesophagogastric devascularization alone.   OGDS= Oesophagogastric 
devascularisation with splenectomy 
 
Participant characteristics 
 Whole study 
(N) 
Shunts Devascularisation Combined/Others 
  PSRS DSRS OGD OGDS  
Age (mean±SD, median, 
range, ) 
      
Sex of participants (n) 
(Male/Female) 
Male/Female      
Child-Pugh Class(A,B,C)      
 Shunts Devascularisation Combined/Others 
Parameters of Liver function 
before intervention. 
(Mean±SD) 
PSRS DSRS OGD OGDS  
Total Bilirubin      
Conjugated Bilirubin      
AST      
ALT      
Prothrombin time/ INR      
Serum Albumin      
Others      
Parameters of Liver function 
after intervention.  
(Mean±SD) 
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Trial characteristics 
 
Study design: Ο Parallel group  Ο Cross-over  Ο Open label 
 Comments: 
 
Intervention: Ο Treatment Ο Other 
 
Total Bilirubin 
Conjugated Bilirubin      
AST      
ALT      
Prothrombin time/ INR      
Serum Albumin      
Others      
Trial characteristics 
 Further details 
Single centre / multicentre  
Country / Countries  
Number of participant recruited  
Number excluded before randomization  
Reasons for exclusion  
Number randomized  
Number of participants in each 
intervention group (Shunt vs 
devascularisation) 
 
Number of participants who received  
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Risk of bias 
intended treatment 
Median (range) length of follow-up reported in 
this paper (state weeks, months or years or if 
not stated) 
 
Number of participants lost to follow up  
Time from bleeding to randomization 
(mean±SD; Range) 
 
Random Sequence generation 
Method: Grade (circle) 
Sequence generation was achieved using computer random number 
generation or a random number table. Drawing lots, coin tossing, 
shuffling cards or envelopes, and throwing dice by an independent 
person 
 
 
Yes/Unclear/No 
Allocation Concealment 
 
Method Grade (circle) 
The participant allocations could not have been foreseen in advance of, 
or during, enrolment. Allocation was controlled by a central and 
independent randomisation unit. The allocation sequence was unknown 
to the investigators (e.g., if the allocation sequence was hidden in 
sequentially numbered, opaque, and sealed envelopes) 
 
Yes/Unclear/No 
  
Blinding of participants and personnel 
 
Method: Grade (circle) 
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Blinding was performed adequately, or the 
assessment of outcomes was not likely to be 
influenced by lack of blinding 
 
Yes/Unclear/No 
Blinding of outcome assessment 
 
Method: Grade (circle) 
Blinding was performed adequately, or the 
assessment of outcomes was not likely to be 
influenced by lack of blinding 
 
Yes/Unclear/No 
Incomplete outcome data (Yes/No) 
Method: Grade (circle) 
Missing data were unlikely to make treatment 
effects depart from plausible values. 
 
Yes/Unclear/No* 
 
(* Trial authors to be contacted for information 
on missing data) 
What method was used to handle missing data?  
  
Selective outcome reporting 
Method Grade (circle) 
Study protocol available and all pre-specified 
outcomes of interest in the review have been 
reported in the pre-specified way 
Yes(Low risk) / No(High risk / Unclear 
Study protocol is not available but is clear that 
published reports include all expect outcomes, 
including those that were pre-specified 
Yes / No / Unclear 
For-profit bias 
 
Method: Grade 
The study is free of industry sponsorship or other 
for profit support that may manipulate design, 
conductance or result. 
Yes/No/Unclear 
  
Other bias 
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Were withdrawals described?    Yes       No         not clear       
Discuss if 
appropriate………………………………………………………………………………………… 
………………………………………………………………………………………………………… 
 
Data extraction 
 
Primary outcomes 
 
 
Secondary outcomes 
 
 
Other outcomes 
 
 
Results 
 Adverse Events:         Described         Yes    No 
   If yes   Procedure related  Overall Statistics 
Adverse events:  
Number of adverse events: 
Type Shunts Devascularisation Combined procedure Total 
 PSRS DSRS OGD OGDS   
       
Length of Hospital stay post 
intervention (Mean, 
median) 
      
Total       
 
Study appears to be free of other sources of 
bias 
Yes / No / Unclear 
Give example.  
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Comments:  
Withdrawals due to adverse events:  
 Shunts Devascularisation Combined 
Number of withdrawals   
 
Outcomes for Patient Subgroups: specify subgroups 
Outcome 
 
For Continuous data   
 
 
Outcome 
 
Unit of 
measurement 
(n = number of 
participants, 
not number of 
events) 
Shunt Devascularisation Details if outcome only 
described in text 
PSRS 
 
DSRS OGD OGDS P-value 
       
 
 
For Dichotomous data   
 
 
Outcome 
 
Unit of 
measurement 
(n = number 
of 
participants, 
not number 
of events) 
Shunt Devascularisation Details if outcome only 
described in text 
PSRS 
 
DSRS OGD OGDS P-value 
       
 
 
Other information which are relevant to the results or any other comment that should be followed up 
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Appendix 2: Search strategy 
 
SPS vs devascularisation procedures for variceal bleeding due to hepatosplenic 
schistosomiasis  
(C Ede) 
Updated searches performed 6 May 2016. 
 
Total number of references identified:  1845 references  
Number of duplicates excluded:    701 references 
Number of references in final list:              1144 references  
Number of new references:               82 references 
 
BATCH NAME: 160506_C Ede_ SPS vs devascularisation procedure 
 
Cochrane Hepato-Biliary Group Controlled Trials Register (May 2016) (131 hits) 
(((port*systemic or portacaval or mesocaval or splenorenal or surgical or selective or non-
selective or partial or total) and (shunt* or anastomos*)) or ('dean warren shunt*' or H-shunt* 
or PSS or devasculari*ation)) AND (varic* and (h*emorrhag* or bleed* or rebleed*)) 
Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 4 of 12, 2016) (238 
hits in CENTRAL) 
#1 MeSH descriptor: [Portasystemic Shunt, Surgical] explode all trees 
#2 ((port*systemic or portacaval or mesocaval or splenorenal or surgical or selective or 
non-selective or partial or total) and (shunt* or anastomos*)) or ('dean warren shunt*' or H-
shunt* or PSS or devasculari*ation)  
#3 #1 or #2  
#4 MeSH descriptor: [Esophageal and Gastric Varices] explode all trees 
#5 MeSH descriptor: [Schistosomiasis] explode all trees 
#6 varic* and (h*emorrhag* or bleed* or rebleed*)  
#7 #4 or #5 or #6  
#8 #3 and #7 
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MEDLINE (Ovid SP) (1946 to May 2016) (302 hits) 
1. exp Portasystemic Shunt, Surgical/ 
2. (((port*systemic or portacaval or mesocaval or splenorenal or surgical or selective or non-
selective or partial or total) and (shunt* or anastomos*)) or ('dean warren shunt*' or H-shunt* 
or PSS or devasculari*ation)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
3. 1 or 2 
4. exp "Esophageal and Gastric Varices"/ 
5. exp Schistosomiasis/ 
6. (varic* and (h*emorrhag* or bleed* or rebleed*)).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
7. 4 or 5 or 6 
8. 3 and 7 
9. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
10. 8 and 9 
 
EMBASE (Ovid SP) (1974 to May 2016) (514 hits) 
1. exp portosystemic anastomosis/ 
2. (((port*systemic or portacaval or mesocaval or splenorenal or surgical or selective or non-
selective or partial or total) and (shunt* or anastomos*)) or ('dean warren shunt*' or H-shunt* 
or PSS or devasculari*ation)).mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
3. 1 or 2 
4. exp esophagus varices/ 
5. exp schistosomiasis/ 
6. (varic* and (h*emorrhag* or bleed* or rebleed*)).mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
7. 4 or 5 or 6 
8. 3 and 7 
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9. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
10. 8 and 9 
 
Science Citation Index Expanded (1900 to May 2016) (661 hits) 
#5 #4 AND #3 
#4 TS=(random* or blind* or placebo* or meta-analys*) 
#3 #2 AND #1 
#2 TS=(varic* and (h*emorrhag* or bleed* or rebleed*)) 
#1 TS=(((port*systemic or portacaval or mesocaval or splenorenal or surgical or selective or 
non-selective or partial or total) and (shunt* or anastomos*)) or ('dean warren shunt*' or H-
shunt* or PSS or devasculari*ation)) 
 
